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ABSTRACT
Objective: The purpose of this study was to determine the ex vivo human placental transfer of
rifampin and rifabutin.
Methods: Seven placentas from uncomplicated, term vaginal or cesarean deliveries were studied
utilizing the ex vivo single cotyledon perfusion system. Antipyrine was used for the reference
compound in the determination of the clearance indices of rifampin and rifabutin.
Results: The clearance indices of rifampin at maternal concentrations of 1.0 and 10.0 pg/ml were
0.12 0.05 and 0.12 0.11, respectively. The clearance indices of rifabutin at maternal concen-
trations of 1.0 and 10.0 pg/ml were 0.44 0.11 and 0.37 0.15, respectively.
Conclusions: Because of its greater lipophilicity, rifabutin was found to have a greater clearance
than rifampin. However, because of rifabutin’s trend toward greater deposition in tissue, there was
proportionately less accumulation of rifabutin in the fetal circulation when compared to rifampin.
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ifamycins are a class of antimicrobials that are
macrocyclic products of Streptomyces mediterra-
nei. The best known member of this class of anti-
biotics is rifampin, a derivative of rifamycin B,
which is very effective in the treatment of Myco-
bacterium tuberculosis infections, when combined
with isoniazid. Rifampin has a molecular weight of
822.95 g/tool and is lipophilic with a octyl alcohol to
water (O/W) ratio of 16 at a pH of 7.4. It inhibits
the DNA dependent RNA polymerase at the B
ribosomal subunit. This inhibitory action is not
noted in eukaryotic cells. 1,z
Another member of this class of antibiotics is
rifabutin, a semisynthetic derivative of rifamycin S,
which is currently used in immunosuppressed in-
dividuals to provide prophylaxis against and treat-
ment for J/. avium complex (MAC) infections.3,4
Rifabutin has also been shown to be effective in
treating primary M. tuberculosis infections and cases
of drug resistant M. tuberculosis, s Rifabutin’s mo-
lecular weight is 847.02 g/mol and is also lipophilic
with an O/W ratio of 2,562 at a pH of 7.0. Rifabu-
tin’s mechanism of action is similar to that of all
rifamycins in that it also inhibits the microbe’s
DNA dependent RNA polymerase, a,z
Even though rifamycins were initially thought
to be potentially teratogenic because of their ability
to inhibit DNA dependent RNA polymerase, cur-
rent evidence would indicate that they are safe for
use in pregnancy. In one study of 446 pregnancies,
the rate of malformations after exposure to ri-
fampin was 3-4%, which is similar to that of the
general obstetrical population and therefore is not
thought to be significant.6 There have been no
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studies of rifabutin use during human pregnancy.
Rifabutin, therefore, has a category B rating by the
Food and Drug Administration.
There is a paucity of studies in the literature
regarding the transplacental passage of rifamycins.
One study of rifampin use in early pregnancy ana-
lyzed the placental, fetal tissue, and amniotic fluid
concentration of rifampin in a 13 week abortus.
The patient had been receiving rifampin twice
daily since the 2nd week of the gestation and re-
ceived an oral dose of rifampin 4 h prior to the
abortion. Rifampin was detected in all of the tissue
analyzed. 7 Another study of the maternal-fetal
transfer of rifamycins determined the rifampin con-
centrations in the neonate’s blood,s
Rifampin’s dosing during pregnancy typically
follows the general guidelines of 10-20 mg/kg/day
(given orally) up to a maximum daily dose of 600
rag/day. 9 Rifabutin, when used as prophylaxis
against MAC, is given as a single daily dose of 300
mg orally. 3 Rifabutin prophylaxis is considered
when patients with Centers for Disease Control
(CDC) defined acquired immunodeficiency syn-
drome (AIDS) have a CD4 count of <200 cells/pl.
MATERIALS AND METHODS
Rifampin and rifabutin were purchased and do-
nated from Sigma Chemical Company (St. Louis,
MO) and Adria Laboratories, Inc. (Dublin, OH),
respectively.
The placentas utilized in this study were col-
lected from term, uncomplicated, spontaneously
delivered vaginal or cesarean delivered pregnancies
in accordance with the guidelines set by the Insti-
tutional Review Board for Human Studies. The
placentas were transferred from labor and delivery
to the laboratory in normal saline in an aseptic man-
ner. On arrival in the laboratory, the placenta’s fetal
artery and vein were cannulated with umbilical ar-
tery catheters. The total time from delivery to per-
fusion was approximately 7-10 min. The cannu-
lated cotyledon was then gently perfused with Ea-
gle’s media and examined for evidence of loss of
membrane integrity. Placental cotyledons that
were noted to have fetal-to-maternal leaks were
discarded. If there were no detectable leaks, the
cotyledon and a portion of the placenta were trans-
ferred to a temperature controlled chamber and
perfused with drug-free media for 20 min to re-
move any residual blood and stabilize the system.
During this initial perfusion, the volume of the fe-
tal perfusate was monitored closely for evidence of
vascular leaks. The placental membrane integrity,
clearance index, and transport fraction were deter-
mined by utilizing the 14C antipyrine method of
Challier.1 A transfer fraction of >40% was deemed
representative of a maternal-fetal circulatory match.
Both rifampin and rifabutin were studied sepa-
rately and at two maternal concentrations (1.0 and
10.0 pg/ml) in both an open/open (non-
recirculating) and a closed/closed (recirculating)
system. Four placental perfusions were performed
for the rifampin studies and three perfusions for
the rifabutin studies. The maternal and fetal com-
partments consisted of 150 ml of medium, which
was aerated via a frittered glass filter with a gaseous
mixture of 95% air and COe. Both maternal and
fetal compartments were continuously mixed by a
magnetic stir bar. The fetal flow rate was set at 3-4
cc/min and the maternal flow rate was set at 17
cc/min.
Clearance indices of the two compounds were
determined by perfusing a known concentration of
the compound through the maternal circulation
and collecting serial aliquots from the fetal circula-
tion for analysis. During the determination of the
clearance indices, the maternal and fetal circula-
tions were open/open (i.e., non-recirculating).
The accumulation of rifampin and rifabutin in
the fetal compartment was determined by placing a
known concentration of the compound in the ma-
ternal circulation and perfusing the placenta in a
recirculating manner (closed/closed). Again, serial
aliquots were obtained every 10 min for h to
determine the accumulation of the antimicrobial.
At the completion of the closed/closed perfusion of
the 10 pg/ml experiment, the apparatus was care-
fully dismantled and an approximate 10 g sample of
placental tissue was retrieved from the center of
the blanched area of the perfused cotyledon for
tissue concentration determination.
Concentrations of rifampin and rifabutin were
determined by high performance liquid chromatog-
raphy (HPLC)which utilized the 254 nM (ultra-
violet) absorption spectrum for rifamycins and a
standard C-18 bond-a-pack column (Waters Asso-
ciation, Milford, MA) and a mobile phase which
was a modification of a published method for the
isocratic determination of rifamycin-derived
agents.
1 The modified mobile phase consisted of
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TABLE I. Clearance indices of rifampin and rifabutin
from the perfusion studies utilizing an ex vivo
human placenta with both the maternal and fetal
circulations open (non-recirculating)
Concentration
Drug (lg/ml) Clearance index P
Rifampin (n 4) 1.0 0.12 + 0.05
Rifabutin (n 3) 1.0 0.44 + 0.11 0.01"
Rifampin (n 4) 10.0 0.12 + 0.
Rifabutin (n 3) 10.0 0.37 + 0.15 0,05*
"Each value represents the mean + standard deviation, of 6 samples over
Ih.
*Significant difference.
50% acetonitrile for rifabutin and 40% acetonitrile
for rifampin. These mobile phases were buffered
by a 0.05 M KHzPO4 solution at a pH of 4.5. Per-
fusates and tissue samples were extracted with a
one-to-one volume of 6% trichloroacetic acid. Re-
producibility studies were determined for both ri-
fampin and rifabutin.
Statistical analysis was performed by utilizing
the t-test for the comparison of mean values be-
tween the two groups of data.
RESULTS
Reproducibility studies for the HPLC determina-
tion of both rifampin and rifabutin concentrations
in the perfusates and tissue samples were >9S%
with a minimum sensitivity of <0.1 pg/ml (data not
shown).
Determinations of the clearance indices of ri-
fampin and rifabutin revealed that rifabutin had a
significantly higher clearance index than that of
rifampin at both the 1.0 and 10.0 pg/ml concentra-
tions (Table 1). There was no significant difference
between rifampin’s or rifabutin’s accumulation in
the fetal compartment (Table 2).
The determination of rifampin’s and rifabutin’s
placental tissue concentrations noted a higher con-
centration of rifabutin in the tissue when compared
to rifampin, but this was not statistically significant
(Table 3). Rifabutin perfused placental tissue was
noted to have 100% of the concentration of the
maternal compartment. As expected, there was an
appropriate decrease in the concentration of each
drug in the maternal perfusate at the end of the
closed/closed (recirculating) perfusion study
(Table 4).
TABLE 2. Comparison of the accumulation of
rifampin and rifabutin in the fetal compartment from
perfusion studies utilizing an ex vivo human placenta
with the maternal and fetal circulations
closed (recirculating)
Fetal
compartment
Concentration concentration at
Drug (lg/ml) 60 min (lg/ml) P
Rifampin (n 4) 1.0 0.21 -I-0.09
Rifabutin (n 3) 1.0 0.18 + 0.12 0.7*
Rifampin (n 4) 10.0 1.31 + 1.78
Rifabutin (n 3) 10.0 0.86 +_ 0.45 0.69*
"Each value represents a total accumulation of 24 samples (n 4).
bStandard deviation.
*Not significant.
TABLE 3. Comparison of placental tissue
concentrations of rifampin and rifabutin after 60
min of perfusion of a 10 lug/ml solution through an
ex vivo human placental cotyledon with the
circulations closed (recirculating)
Placental tissue
Drug concentration (lg/g) P
Rifampin (n 4) 3.37 + 0.64 (27%)
Rifabutin (n 3) 11.7 -I- 8.7 (100%) 0.105"
aStandard deviation.
*Not significant.
TABLE 4. Initial concentration of rifampin and
rifabutin in the maternal perfusate of an ex vivo
human placenta
Drug
Maternal compartment Actual maternal
concentration concentration
(lg/ml) (lg/ml)
Rifampin (n 4) 1.0 0.86 + 0.58
10.0 12.4 + 3.4
Rifabutin (n 3) 1.0 I. 17 + 0.12
10.0 11.7 + 1.98
aStandard deviation.
DISCUSSION
This comparison of rifampin and rifabutin in the ex
vivo placental model noted a significant difference
in the placental transfer of the two compounds.
These differences can be explained by the differ-
ence in their lipophilicities. Rifabutin is several or-
ders of magnitude more lipophilic than rifampin
and therefore crosses the placenta more readily.
Because of a large standard deviation in the analy-
sis of the placental tissue concentration of rifabu-
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tin, the apparent difference did not reach statistical
significance. However, because of its greater lipo-
philicity, rifabutin is more likely than rifampin to
accumulate in the placental tissue. A comparison of
tissue to plasma ratios from studies in non-pregnant
patients reveals a greater ratio for rifabutin than
rifampin. Specifically, these ratios were 1.05 to 0.83
for rifampin vs. 1.5 to 8.5 for rifabutin,s,8 This ap-
parent predilection for rifabutin to accumulate in
tissues raises a concern about the drug’s safety in
pregnancy.
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